SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

12 نوفمبر 2024 09:25:59 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

12 نوفمبر 2024 06:30:21 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

11 نوفمبر 2024 07:00:56 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

11 نوفمبر 2024 06:30:11 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

07 نوفمبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

05 نوفمبر 2024 07:00:32 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

22 أكتوبر 2024 07:00:14 بحسب Nasdaq GlobeNewswire

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

28 أغسطس 2024 06:30:35 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

07 أغسطس 2024 06:30:35 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

29 يوليو 2024 06:30:11 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

23 يوليو 2024 07:00:02 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

01 يوليو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

05 يونيو 2024 07:00:52 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 مايو 2024 17:13:28 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

08 مايو 2024 07:00:27 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

02 مايو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 أبريل 2024 13:31:32 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

18 أبريل 2024 07:00:28 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

04 مارس 2024 06:30:11 بحسب Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

29 فبراير 2024 08:30:13 بحسب Nasdaq GlobeNewswire